拉米夫定联合前列地尔对慢性肝炎患者CD3^+ CD25^+ Foxp3^+调节T细胞水平的影响  

Effect of lamivudine combined with alprostadil on level of CD3^+ CD25^+ Foxp3^+ regulation T cells of chronic hepatitis

作　　者：孟杰[1] 鲁素彩[1] 宋红霞[1] 赵淑芹[1] 尹玲[1] 贾宁[1] 

机构地区：[1]河北大学附属医院消化内科,石家庄071000

出　　处：《实用药物与临床》2013年第8期675-678,共4页Practical Pharmacy and Clinical Remedies

摘　　要：目的观察拉米夫定联合前列地尔治疗慢性乙型肝炎(CHB)的疗效及对CD3+ CD25+ Foxp3+调节T细胞水平的影响。方法 2010-2013年我院收治的148例慢性乙型肝炎患者随机分为实验组和对照组,每组74例,两组均接受综合保肝治疗和前列地尔注射,在此基础上实验组口服拉米夫定,对照组口服阿德福韦酯,观察两组患者HBV-DNA阴转率、ALT及CD3+ CD25+ Foxp3+调节T细胞水平变化。结果治疗后两组患者ALT水平均呈下降趋势,实验组在6、12、24、72周时显著低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者HBV-DNA阴转率均逐渐升高,在24周后实验组显著高于对照组(P<0.05)。在中度、重度CHB治疗后,实验组Treg水平显著低于对照组(P<0.05)。结论拉米夫定联合前列地尔能有效抗病毒,保护肝细胞,对慢性乙型肝炎有较好的治疗效果,能显著降低CD3+ CD25+ Foxp3+调节T细胞水平。Objective To study the effect of lamivudine combined with alprostadil on level of CD3 ＋ CD25 ＋ Foxp3 ＋ regulation T （Treg）cells of chronic hepatitis.Methods 148 patients with chronic hepatitis B （CHB）during 2010-2013 were randomly divided into experimental group and control group.Both groups received comprehensive treatment and alprostadil,experimental group was given lamivudine while control group was given adefovir dipivoxil.The HBV-DNA negative rate and level of ALT and CD3 ＋ CD25 ＋ Foxp3 ＋ Treg cells of the two groups were observed.Results The level of ALT of both groups decreased after treatment,and experimental group was significantly lower than control group at 6 weeks,12 weeks,24 weeks and 72 weeks after treatment（P ＜ 0.05）.Both groups had rising rate of HBV-DNA negative,and experimental group was significantly higher than control group at 24 weeks after treatment.Treg cells level of experimental group was lower than that of control group after treatment （P ＜ 0.05）.Conclusion Lamivudine combined with alprostadil can reduce virus,protect hepatic cells and decrease the level of CD3 ＋ CD25 ＋ Foxp3 ＋ Treg cells,it has good effect on CHB.

关 键 词：拉米夫定 前列地尔 慢性肝炎 CD3＋ CD25＋ Foxp3＋调节T细胞 

分 类 号：R512.62[医药卫生—内科学]